

COMPLETE LISTING OF ALL CLAIMS WITH MARKINGS  
AND STATUS IDENTIFIERS

(Currently amended claims showing deletions by ~~strike-through~~ and additions by underlining.)

1. - 31. (Cancelled)

32. (Amended) A pharmaceutical composition for the treatment of hyperlipidemia in a patient in need thereof, comprising a therapeutically effective amount of a somatostatin type-5 receptor selective agonist, wherein said therapeutically effective amount is an amount that is effective for the treatment of hyperlipidemia in said patient.

33. (Cancelled)

34. (Previously Presented) A pharmaceutical composition according to claim 32, wherein said somatostatin type-5 receptor agonist has a  $K_i$  of less than 2 nM for the somatostatin type-5 receptor.

35. (Previously Presented) A pharmaceutical composition according to claim 32, wherein said somatostatin type-5 receptor agonist has a  $K_i$  for the type-5 somatostatin receptor that is at least 10 times less than its  $K_i$  for the somatostatin type-2 receptor.

36. - 37. (Cancelled)

38. (Amended) A pharmaceutical composition for lowering the amount of triacylglycerols in the blood of a patient in need of such lowering, comprising a therapeutically effective amount of a somatostatin type-5 receptor selective agonist, wherein said therapeutically effective amount is an amount that is effective for lowering the amount of triacylglycerols in the blood of said patient.

39. (Cancelled)

40. (Previously Presented) A pharmaceutical composition according to claim 38, wherein said somatostatin type-5 receptor agonist has a  $K_i$  of less than 2 nM for the somatostatin type-5 receptor.

41. (Previously Presented) A pharmaceutical composition according to claim 38, wherein said somatostatin type-5 receptor agonist has a  $K_i$  for the type-5 somatostatin receptor that is at least 10 times less than its  $K_i$  for the somatostatin type-2 receptor.

42. - 43. (Cancelled)

44. (Amended) A pharmaceutical composition for lowering the amount of glycerol in the blood of a patient in need of such lowering, comprising a therapeutically effective amount of a somatostatin type-5 receptor selective agonist, wherein said therapeutically effective amount is an amount that is effective for lowering the amount of glycerol in the blood of said patient.

45. (Cancelled)

46. (Previously Presented) A pharmaceutical composition according to claim 44, wherein said somatostatin type-5 receptor agonist has a  $K_i$  of less than 2 nM for the somatostatin type-5 receptor.

47. (Previously Presented) A pharmaceutical composition according to claim 44, wherein said somatostatin type-5 receptor agonist has a  $K_i$  for the type-5 somatostatin receptor that is at least 10 times less than its  $K_i$  for the somatostatin type-2 receptor.

48. - 49. (Cancelled)

50. (Amended) A pharmaceutical composition for lowering the amount of cholesterol in the blood of a patient in need of such lowering, comprising a therapeutically effective amount of a somatostatin type-5 receptor selective agonist, wherein said therapeutically effective amount is an amount that is effective for lowering the amount of cholesterol in the blood of said patient.

51. (Cancelled)

52. (Previously Presented) A pharmaceutical composition according to claim 50, wherein said somatostatin type-5 receptor agonist has a  $K_i$  of less than 2 nM for the somatostatin type-5 receptor.

53. (Previously Presented) A pharmaceutical composition according to claim 50, wherein said somatostatin type-5 receptor agonist has a  $K_i$  for the type-5 somatostatin receptor that is at least 10 times less than its  $K_i$  for the somatostatin type-2 receptor.

54. - 55. (Cancelled)